Abiopharma

🔍 Krepp Sarah (Executive)

Company: Liquidia Corp (LQDA)

Report Date: 2025-08-29

Detailed Transactions and Holdings:

• Sold 209 shares of Common Stock at $29.05 per share (Direct)
  Date: 2025-08-29 | Code: S | equity_swap_involved: 0 | shares_owned_after: 143,130.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3

Footnotes:

• F1: Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
• F2: These shares were sold to cover taxes associated with the settlement of restricted stock units ("RSUs").
• F3: Includes (i) 36,540 unvested RSUs of the 61,465 RSUs granted to the Reporting Person on January 11, 2024, (ii) 9,344 unvested RSUs of the 12,459 RSUs granted to the Reporting Person on July 1, 2024, (iii) 50,861 RSUs granted to the Reporting Person on January 11, 2025, none of which have vested as of July 14, 2025, (iv) 25,000 RSUs granted to the Reporting Person on July 1, 2025, none of which have vested as of the date of this Form 4 and (v) 5,312 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.